Early childhood growth patterns are associated with adult metabolic health, but the underlying mechanisms are unclear.
Introduction
Complex developmental processes regulate changes in body mass and growth in early life. Multiple genetic variants are robustly associated with adult body mass index (BMI) 1 and metabolic phenotypes [2] [3] [4] but much fewer data exist for childhood traits 5, 6 . Discrete genetic variants may regulate developmental patterns during rapid growth in infancy compared to later growth periods in childhood 7 as demonstrated by the age-dependent impact of variation at the FTO locus on BMI 8 but there still remains a paucity of relevant data. On the other hand, robust observational associations between early growth traits and adult cardiometabolic risk [9] [10] [11] [12] may, in part, be explained by shared genetic factors. In support of this hypothesis, studies from the Early Growth Genetics (EGG) consortium show that some of the genetic component contributing to size at birth also impacts type 2 diabetes, cardiovascular disease and blood pressure 13 .
However, the extent of the genetic correlation between postnatal growth patterns and the regulation of adult body weight, energy metabolism and later metabolic health is unclear.
In infancy and childhood, individuals follow well-characterized and predictable height, weight and BMI trajectories (Figure 1) 14 . For example, BMI trajectory encompasses three periods characterized by i) a rapid increase in BMI up to the age of 9 months (adiposity peak, AP); ii) a rapid decline in BMI up to the age of 5-6 years (adiposity rebound, AR);
and iii) a steady increase in BMI after 5-6 years until early adulthood 10 . Here, we set out to model sex-specific individual weight, height and BMI curves in children, using unique data collected from primary health care or clinical research visits, to extract six early growth traits: peak height velocity (PHV; cm/month), peak weight velocity (PWV; kg/month), age at adiposity peak (Age-AP; year), BMI at adiposity peak (BMI-AP, kg/m 2 ), age at adiposity rebound (Age-AR; year), BMI at adiposity rebound (BMI-AR, kg/m 2 ) (Figure 1 ) and to test for genetic associations using genome-wide genotype data. Although a few previous studies have investigated the genetic basis of these well-established measures of longitudinal growth trajectory 7, 9, 15, 16 , no systematic genome-wide analyses have been carried out to date. Understanding the genetic architecture of early childhood growth phenotypes will provide insight into their regulation and into the mechanisms underlying the observed associations with adult cardiometabolic disease, which will be fundamental for early promotion of metabolic health.
Results

Genome-wide association meta-analyses of early growth phenotypes
We conducted genome-wide association study (GWAS) meta-analyses to identify genetic loci influencing each of the six early growth traits in up to 7,215 term-born children of European ancestry from up to four population-based studies that had both genetic and early growth trait data (stage 1; Online Methods, Supplementary Figure 1) . From the stage 1 inverse variance meta-analyses, we selected a total of 8 loci with either P < 1 x 10 -7 or with P < 1 x 10 -5 in/near genes known to be associated with obesity and metabolic traits in published GWAS or candidate gene studies (Supplementary Table 2) , and sought confirmation in up to 16 ,550 term-born children from up to 11 additional studies (stage 2; Online Methods, Supplementary Table 3 , Supplementary Figure 1) . Our study design is summarized in Figure 2 , while participant characteristics, genotyping arrays, imputation and quality control for the discovery and follow-up studies are summarized in Supplementary Tables 1 and 3 . In combined meta-analyses of the discovery and follow-up studies (including up to 22,769 children), we identified common variants at four independent loci, each associated with any of the early growth phenotypes, at genome-wide levels of significance (i.e. P < 5 x 10 at the FTO (encoding a 2-oxoglutarate-dependent demethylase) and rs2817419 at the TFAP2B (encoding transcription factor AP-2 beta) loci associated with Age at AR, and rs10938397 near the GNPDA2 (encoding adiposity regulating glucosamine-6-phosphate deaminase) locus associated with BMI at AR. The lead signals at each of the four loci were located within non-coding regions of the relevant genes except for rs10938397, which was located in an intergenic region proximal to the GNPDA2 gene (Figure 3) . The common AR-associated SNPs at FTO, TFAP2B and GNPDA2 have previously been associated with other anthropometric measures, especially in adulthood 1 . However, the three loci LEPR/LEPROT, TFAP2B and GNPDA2 described here are novel with respect to their association with early growth phenotypes, while the association between SNPs at FTO and Age at AR in the current study replicates the findings of a previous gene-centric study 8 at genome-wide levels of significance.
At the LEPR/LEPROT locus, the minor G allele of rs9436303 was associated with higher BMI at AP, 0.07SD per allele (95% CI= 0.04, 0.09), Pcombined = 5.1 x 10 -9
, equivalent to a difference of 0.07 kg/m 2 (95% CI= 0.05, 0.09) per effect allele. The same allele is also associated with earlier age at menarche (P= 0.00019 in the ReproGen consortium's publically available age at menarche GWAS data) 17 and with increased plasma soluble leptin receptor levels (P=1.19 x 10 Table 4 ). Using data from the Northern Finland Birth Cohort (NFBC) 1966 study (N=2585) we also show that the previously published genome-wide significant SNPs associated with other traits in the LEPR/LEPROT locus are not associated with BMI at AP, and that our index SNP rs9436303 remains associated with BMI at AP (P< 1x10 -6 ) after conditioning on those other trait-associated SNPs (Online Table 5) . Therefore, to our knowledge, rs9436303 represents a novel, distinct, signal for BMI at AP at this locus.
Methods and Supplementary
At the FTO locus, the C allele of the index SNP rs1421085 was associated with earlier Age at AR, -0.12 SD per allele (-1.44 months, 95% CI= -1.42, -1.46), Pcombined = 3.12 x 10 -30 , and is directionally consistent with a previous gene-centric study 8 .
The FTO locus has the largest effect on BMI and obesity risk reported in GWAS carried out to date, and the same allele that is associated with earlier Age at AR is associated with higher childhood and adult BMI 22 . Table 6 ). However, rs2207139 is in very low LD (r 2 = 0.035) with our index SNP rs2817491, and these are likely to represent two distinct signals at this locus. In support of this, conditional analyses in the NFBC1986 data adjusting the effect of rs2817419 on Age at AR for rs2207139 and vice versa showed that the two SNPs have independent effects on Age at AR (-0.07 SD (95% CI= -0.13, -0.01), P=0.03 and -0.10 SD (95% CI= -0.17, -0.03), P=0.007 respectively) (Online Methods).
Overall, the identified associations at FTO and TFAP2B are directionally consistent with observational associations between the timing of AR and adult BMI 9 (i.e. reaching AR at an earlier age is associated with higher BMI whereas reaching AR later is associated with lower BMI).
At the GNPDA2 locus, the G allele of the index SNP rs10938397 was associated with higher BMI at AR, 0.06 SD per allele , with the same allele being associated with higher adult BMI in previous reports 30 .
There was no heterogeneity between the studies, except at LEPR/LEPROT (Supplementary Figure 3) . For example, in the fixed effect meta-analysis of the discovery stage results for the BMI at AP associated SNP rs9436303 in LEPR/LEPROT locus showed heterogeneity (Supplementary Figure 3a) and random effect meta-analysis did not change the heterogeneity (Supplementary Figure 3b) . However, excluding the smaller LISA-D study (N=282) that showed directionally inconsistent effects to the other studies, from the discovery stage meta-analysis for this SNP reduced the heterogeneity but did not change the point estimates (Supplementary Figure 3c) . Similarly, there was heterogeneity in the combined stage fixed meta-analysis for the same SNP in LEPR/LEPROT (Figure 3d) , and random effect meta-analysis did not change the heterogeneity (Figure 3e) . Fixed effect meta-analysis excluding the EDEN and NFBC1966 studies that showed inflated results showed no heterogeneity, and the point estimates were similar with and without the two studies ( Supplementary Figure 3f & 31, 32 , RPGRIP1L 33 and IRX3/IRX5 in the IRXB gene cluster 34, 35 have been implicated as the candidates for mediating the observed associations with adult adiposity. Given our index SNP at FTO associated with Age at AR is highly correlated with the BMI associated SNPs at the same locus, it is plausible that the same genes play a role in the regulation of Age at AR and adult adiposity.
To identify other potential candidate genes and provide further insights into the molecular mechanisms underlying the four genome-wide significant loci associated with BMI at AP, BMI at AR or Age at AR, we searched for association of the index SNP with cis-acting expression quantitative trait loci (eQTLs) in five different living tissues: liver, skin, whole blood and subcutaneous and omental fat, and repeated these lookups in 44 post-mortem tissues from the Genotype-Tissue Expression (GTEx) consortium 36 (Online Methods), which mostly reproduced the results of the eQTL association in living tissues. For two out of the four loci analysed, the index SNP was strongly associated (at P < 0.001) with the expression of one or more nearby (+/-1 Mb) genes (Supplementary Table 8 ) gene expression levels in subcutaneous fat. The consistency of the results for this locus across five different tissues and in four different datasets (MuTHER, KORA, deCODE and Kaplan) suggests that these findings are robust and imply that, at least for this locus, the underlying causal variant functions through gene expression. Both the LEPR and LEPROT genes are good biological candidates for having a role in the regulation of BMI at AP in infancy because the LEPR gene encodes the receptor for leptin, an adipocyte-specific hormone that plays a major role in the regulation of appetite and energy balance, reproduction, growth and the immune system 37, 38 . Variation in leptin concentrations is also associated with adult body mass 38 and rare mutations in the LEPR gene cause monogenic obesity 39 . The LEPROT gene negatively regulates LEPR cell-surface expression 40 and growth hormone (GH) receptor expression in the liver 41 , thereby decreasing hepatic responses to leptin and growth hormone. This is consistent with the finding by Wu et al 42 in mice showing that LEPROT could be central to the nutritional regulation of growth and growth hormone binding in the liver and chondrocytes. This evidence further suggests a role for LEPROT in the hepatic synthesis of the insulin-like growth factor 1 (IGF-1) 42 . The BMI at AR associated index SNP rs10938397 in GNPDA2 was associated with GUF1 (GUF1 Homolog, GTPase) transcription in subcutaneous fat (P=7.10 x10 Table 8 ).
To explore the biological pathways and networks underlying early growth, we applied a gene set enrichment analysis (MAGENTA) 43 to the discovery stage GWAS results (Online Methods). We identified enrichment of two gene sets (Supplementary Tables 9 and 10 . This hypothesis suggests that the risk of childhood obesity associated with high-protein intake during lactation could be caused by stimulation of the IGF-1/GH pathway leading to an early age at adiposity rebound. It is therefore possible that higher IGF-1 levels, via genetic and/or nutritional factors, might reduce GH levels and expression via a negative feedback 48, 49 . Subsequent, lower circulating levels of GH might also suppress lipolysis and contribute to fat accumulation 50, 51 , potentially affecting normal BMI trajectories and Age at AR, and thereby risk of adult obesity and metabolic disorders. 
Association of the adult BMI associated loci with early growth traits
In a look-up analysis of the 97 adult BMI associated loci from the GIANT consortium 1 in our stage 1 GWAS meta-analysis data, we observed that an excess of adult BMI increasing alleles was associated (P<0. Figure 4) . Furthermore, we observed correlations (at P<0.0001) between the effects of the 97 adult BMI associated SNPs, and Age at AR and BMI at AR (Figure 4 ) but no correlations were observed with the effects on the other early growth phenotypes (Supplementary Figure 5) . Taken together our results suggest that the variants involved in the regulation of adult BMI have effects that begin in early childhood, around the age at AR.
Genetic link between early growth and health outcomes
To further explore the genetic links and, thereby, help prioritize the potential causal relationships between early growth and adverse health outcomes, we estimated their genetic correlation using LD score regression (Online Methods). In contrast to observational associations, genetic correlations between complex traits can be useful in prioritizing observational associations for subsequent causal analyses, as genetic factors are less likely to be confounded and are not altered by the outcome. Here we summarize the key genetic correlations at 1% FDR, and full results are presented in Figure 5 and Supplementary ).
In contrast to Age at AR, BMI at AR revealed an inverse genetic correlation with age at menarche (rg=-0.38, P=4.48 x 10 ). Together the genetic correlations of Age at AR and BMI at AR with age at menarche and BMI are directionally consistent given that earlier age at menarche predicts higher adult BMI 54 and both are associated with adverse cardiometabolic traits in observational studies [55] [56] [57] .
In summary, the results from LD score regression analysis define a robust link between the genetics of early growth and the genetics of later BMI and childhood /adult obesity. In contrast, the LD score regression analysis revealed relatively little evidence for a shared genetic link between early growth traits and lipid metabolism, blood pressure, type 2 diabetes or cardiovascular disease.
Discussion
We report the first GWAS of six early growth phenotypes derived from longitudinal data. In samples of up to 22, 769 term-born children of European descent, we exploited a wealth of repeated weight and height data collected from birth until 13 years. These more refined phenotypes better capture childhood growth patterns relevant to later disease risk than single growth measures in childhood such as BMI and height. The four common variants identified here show consistent effects across several studies despite varying study designs, sample collection methods, and containing data obtained from children born at different geographical regions in Europe demonstrating that our results are robust, and are not affected by any differences between studies. One exception to this is the common variant at LEPR/LEPROT where we observed some evidence for heterogeneity. However, excluding the studies that showed inflated results from the meta-analyses reduced or showed no heterogeneity, and did not change the point estimates. Our findings contribute to the understanding of genetic influences on early growth in humans, and provide insights into the underlying molecular mechanisms that link early growth phenotypes with increased risk of obesity in later childhood and adulthood. An exception to this is the common variant in the LEPR/LEPROT locus associated with BMI at AP that was not associated with later obesity in childhood or adulthood, although other common variants in this gene are associated with childhood obesity and several metabolic traits, and rare mutations in the same gene cause early onset morbid obesity (OMIM ID: 614963) 39, 58 . This raises questions about how the yet-to-be-determined causal variant at LEPR/LEPROT, or the leptin/free leptin surge in infancy, impact on early development and health. It is noteworthy that research in animals has identified an early peak in leptin concentration, which is thought to be essential not only in regulating energy balance but also in brain development 59 .
Our study has limitations that should be taken in to consideration for future genetic studies of early growth traits. First, dense longitudinal growth data meshed with GWAS data are only available in a few cohorts worldwide, so we had limited power to detect genetic variants with smaller effects and/or low allele frequencies. This affected our ability to identify robust associations of some of the promising variants identified in the discovery stage, in particular at PCSK1 (Table 1) .
Variants at this locus, which are known to be associated with severe obesity 60 , showed a suggestive association with BMI at AP in our discovery GWAS, but failed to replicate and were not included in further analyses. However, in our discovery stage GWAS for BMI at AP among ~6,222 infants, we had 85% power to detect a variant with an effect size of 0.14 SD at P<5 x10 -8 with minor allele frequency of 0.22. Second, it is noteworthy that these derived growth phenotypes are likely to be influenced by a degree of measurement error, especially in cohorts with fewer repeated measures around the time points being estimated, which in turn could have further hampered our power to detect true genetic associations. Despite this, we were still able to discover genetic variants showing robust associations with these derived growth phenotypes. Third, in the current GWAS we inferred genotypes based on HapMap Phase 2 imputation; imputation using more comprehensive reference panels can provide greater coverage of the genome and can aid in improving power to detect additional genetic variants. Fourth, the present results may not be directly applicable to other ethnic groups as growth patterns and disease risk vary by ethnicity. Trans-ethnic studies may help to identify additional genetic risk variants due to differences in allele frequencies among different ethnic groups. For example, the type 2 diabetes-associated locus KCNQ1, which has an effect across multiple ethnic groups, was first discovered in an East Asian GWAS, due to the allele frequency difference between the East Asian and European populations 61 .
Finally,
we did not identify any variants associated with PHV, PWV and Age at AP at genome-wide levels of significance, and this may be due to a combination of smaller genetic effects on growth at this stage of development, reduced statistical power due to smaller sample size or because environmental factors are more influential than genetic influences at this age. The interplay with infant feeding and other environmental factors also warrants additional research.
In conclusion, we have identified three novel loci associated with BMI at AP in infancy at around 9 months, and age and BMI at AR at around 5-6 years, and confirmed the previously reported association of FTO with Age at AR 8 , at genomewide significance levels. The genetic architecture of early growth shares a robust similarity with that of later BMI. For example, the three AR associated loci identified here are strongly associated with adult BMI (Figure 6 ), and the crosstrait genetic correlations based on GWAS data showed the same relationship. The relationship of AR to later adiposity may be due to shared genetic mechanisms or Age at AR and BMI at AR might be on the causal pathway for later adiposity.
To test this hypothesis, large independent study populations are required, in which causal analysis methods such as
Mendelian randomization can be undertaken using the variants associated with these phenotypes as proxies for early growth phenotypes. However, such studies would currently be underpowered as the variants discovered here only explain a small proportion of the variance in the early growth traits. Taken together, our results suggest that adult obesity has its origins in early childhood, and interventions aiming to promote an optimal growth trajectory in infancy and early childhood could contribute to the prevention of obesity.
Methods
Longitudinal growth modeling and derivation of early growth phenotypes
Early growth phenotypes were derived from sex-specific individual growth curves using mixed effects models of height, weight and BMI measurements from birth to 13 years (Figure 1) . All height and weight data were collected prospectively via either self-reported data or clinical measurements (Supplementary Table 1 and 2 ).These phenotypes were derived separately in each cohort (Supplementary Note 4) .
Derivation of peak height velocity (PHV) and peak weight velocity (PWV) -
The methods for growth modeling and derivation of growth parameters from the fitted curves is described in detail in a previous publication 7 Parametric Reed1 growth model was fitted in sex stratified non-linear random-effect model as described previously 62 . Term-born singletons (defined as ≥ 37 completed weeks of gestation) with at least three height or weight measurements from birth to 24 months of age were included in the Reed1 model fitting. Maximum-likelihood method for best fitting curves for each individual was used to estimate the growth parameter, PHV (cm/months) and PWV (kg/months).
Derivation of age and BMI at adiposity peak (AP) and adiposity rebound (AR) -
The methods used for growth modeling of age and BMI has been previously described in detail by Sovio et al, 2011 8 . Due to the specificity of longitudinal changes in BMI i.e. succession of peak and nadir as described in figure 1, the data was divided into two age windows for modeling i) growth in infancy using height and weight data from 2 weeks to 18 months of age and ii) growth in childhood using growth and weight data from 18 months to 13 years of age. Each cohort contributed most data available within any of these two age windows. In studies where the data available consisted of both height and weight data within a given window, then the data point nearest to the mid time points of that window were used as a proxy for the BMI measurement. Prior to model fitting, age was centered using the median age of the relevant age window. For example, in the infant growth model at 0-1.5 years, the median age was 0.75 years (which was close to the average age at AP), and in the childhood growth model at >1.5-13 years, the median age was 7.25 years (on average shortly after AR). Linear
Mixed Effects (LME) models were then fitted for log-transformed BMI. We used sex and its interaction with age as covariates, with random effects for intercepts i.e. baseline BMI, and linear slope i.e. linear change in BMI over time. In addition to linear age effect, quadratic and cubic terms for age were included in the fixed effects to account for nonlinearity of BMI change over time. where BMI is expressed in kg/m 2 and age in year. β0, β1, β2, β3, β4 are the fixed effects terms, u0 and u1 are the individual level random effects and ε is the residual error. The age at AP was calculated from the model as the age at maximum BMI between 0.25 and 1.25 year according to preliminary research 7, 11 .
Growth in Infancy
Growth in Childhood.
The model used to measure the age and BMI at adiposity rebound (AR) in childhood is as follows: 
Stage 1 genome-wide association analyses and meta-analyses
According to the availability of dense enough data for growth modeling, a total of up to 7215, 6222, 6219 and 6051 children were used to analyse PHV/PWV, Age-AP, BMI-AP and Age-AR /BMI-AR respectively (Figure 2) . We only included children who were born between 37 and 41 completed weeks of gestation (i.e.: term born) from singleton pregnancies and children who had more than three growth measurements available within the age range in question. Gestational age was either defined from the date of the last menstrual period or ultrasound scans depending on the study. All six early growth traits except for Age-AP and Age-AR were natural log transformed to reduce skewness, and all traits were converted to z-scores prior to association testing to facilitate the comparison of results across the studies. We tested the directly genotyped and imputed variants for association with each of the six early growth traits in a linear regression model assuming an additive genetic effect. The regression models were adjusted for sex and principal components (PC)
derived from the genome-wide data to control for potential population substructure (the necessary number of principal components included varied by study). The regression models were also adjusted for gestational age, except for Age-AR and BMI-AR. The genome-wide association analyses (i.e. stage 1) were performed using either SNPTEST or MACH2QTL
in each cohort, and data exchange facilities were provided by the AIMS server 63 . All stage 1 study beta estimates and their standard errors were meta-analysed using the inverse-variance fixed effects method in the METAL software 64 . SNPs with poor imputation quality (e.g. r were excluded prior to the meta-analyses. Double genomic control 65 was applied: firstly, to adjust the statistics generated within each cohort and secondly, to adjust the overall meta-analysis statistics. Results are reported as a change in standard deviation (SD) units per effect allele as reported in Table 1 .
Selection of SNPs for stage 2 follow up.
All loci reaching P < 1 x 10 -7 from stage 1 GWAS of each early growth trait were selected for follow-up in stage 2. These included the two SNPs associated with Age-AR in the FTO locus (rs1421085) and in the intergenic region between RANBP3L and SLC1A3 (rs2956578), and the SNP associated with BMI-AP in LEPR/LEPROT (rs9436303). Four further SNPs (one SNP associated with BMI-AP near PCSK1 (rs10515235), one SNP associated with Age-AR in TFAP2B (rs2817419), and two SNPs associated with BMI-AR near GNPDA2 (rs10938397) and in DLG2 (rs2055816)) were selected for followup on the basis of showing an association with an early growth trait at P < 1 x 10 -5 and being in/near genes with established links to adiposity and metabolic phenotypes except for DLG2, a possible candidate gene involved in glucose metabolism 66 . In addition, one locus with a plausible association (P = 5.91 x 10 -5
) with PWV, near TMEM18 (rs2860323), was also selected for follow-up based on previous reports showing an association with severe early onset obesity 19 and its association with BMI in adulthood 29 and childhood 6 (Supplementary Table 3 ). No loci for PHV or AGE-AP passed the p-value threshold or other selection criteria used for follow up. Supplementary Table 3 shows the SNP selection criteria and proxies used in more detail. Study characteristics, genotyping platform, imputation and association test software used, as well as sample and genotyping and imputation quality control steps in each stage 1 study are given in Supplementary Table 2 . We used the same methods as in stage 1 for sample selection, genotyping quality control, association testing and meta-analysis.
Stage 2 follow up of lead SNPs in single SNP association analyses
Combined analysis of stage 1 and stage 2 samples. All stage 1 and 2 results were meta-analysed using the inversevariance fixed effects method in either METAL 64 or R (version 3.2.0; http://www.r-project.org/). In these combined analyses, loci reaching P < 5 x 10 -8 were considered as genome-wide significant and loci reaching P < 5 x 10 -6 were considered as a suggestive association. Heterogeneity between studies was tested by Cochran's Q tests and the proportion of variance due to heterogeneity was assessed using I 2 index for each individual SNP at each stage.
Estimation of genetic variance explained
The variance explained (VarExp) by each SNP was calculated using the effect allele frequency (f) and beta (β) from the meta-analyses using the formula VarExp = β 2 (1 − f)2f.
Analysis of the association of the index SNP associated with early growth phenotypes in other GWAS data sets
We looked up the index SNP or a proxy associated with each early growth trait in publicly available published metaanalysis data sets to assess their associations with other GWAS traits using the Pheno Scanner available at http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner 67 . We used a P-value cut off of <5 x 10 -8 for displaying the association results and r 2 cut off of > 0.6 for proxy SNP lookups from 1000G.
Conditional analyses
To test whether the index SNP (rs9436303) in LEPR/LEPROT locus associated with BMI at AP have an effect on BMI at AP independent of the other trait associated SNPs in the same locus we first, tested the individual association of our index SNP and each of the five previously published genome-wide significant SNPs associated with obesity and metabolic traits in the LEPR/LEPROT locus with BMI at AP using a linear regression model adjusted for sex and gestational age in 3459 children from the NFBC1966 study using the same exclusion criteria described above. We next tested whether our index SNP has an independent effect on BMI at AP, by adjusting the linear regression model between the index SNP and BMI at AP for each of the five previously published genome-wide significant SNPs, sex and gestational age.
To test whether our index SNP (rs2817419) and the adult BMI and waist circumference associated index SNP (rs2207139)
at the TFAP2B locus in GIANT have independent effects on Age at AR we tested the association between rs2817419 and
Age at AR in a linear regression model adjusting for rs2207139 and sex and vice versa in the NFBC1986 study.
Expression quantitative locus (e-QTL) analysis.
To study the molecular mechanisms underlying the significant genetic variants associated with growth patterns, we searched for cis eQTL using results obtained on liver, skin, whole blood and subcutaneous and omental fat living tissue made available by the MuTHER Only 95/97 were used in the NFBC1986 cohort as no suitable proxies were available for two SNPs (rs6477694 and rs2112347). We used the same exclusion criteria applied in the GWAS analyses described above and calculated the weighted score of the 95/97 SNPs using the formula 1 below to account for varying effect sizes of the SNPs. The SNPs were recoded to reflect the number /dosage of the BMI increasing alleles for that SNP. The weight (W) for each locus is the effect size of the BMI increasing allele of each SNP from Locke et al
The weighted genetic risk score was rescaled to reflect the number of BMI-increasing alleles using formula 2 as
We then created quintiles of weighted genetic risk score in each study containing approximately 20% children in each of the five groups, and tested the mean difference in each early growth phenotype between the lowest and the highest quintile of the weighted genetic risk score in a liner regression model. In the linear regression model we used the quintiles of weighted genetic risk score as the independent variable, and each early growth trait as the dependent variable adjusted for sex and gestational age except for Age-AR and BMI-AR where the regression model was only adjusted for sex. The genetic risk score analyses were carried out in StataMP 13 for Windows (StataCorp, Brownsville, TX). The results from NFBC1966 and NFBC1986 cohort was meta-analysed using the fixed effect inverse variance estimator implemented in the Stata command, "metan".
Linkage-disequilibrium (LD) score regression analyses
The use of LD score regression in estimating the genetic correlation between two traits have been described previously 73, 74 . Briefly the LD score regression uses GWAS meta-analysis summary statistics of several million SNPs of the two traits under comparison (here the GWAS meta-analysis summary statistics of each early growth trait and the other trait under comparison) and calculates the cross product of the test statistics at each SNP. This cross product of the test statistics is then regressed against the LD score of each SNP (i.e.: sum of the LD r 2 between a variant and all the variants in a 1 cm region in the genome) and the slope of this regression line gives the genetic correlation between the two traits of interests. We primarily used the LD hub 75 available at http://ldsc.broadinstitute.org to quantify the genetic correlation between each of the five early growth traits, and health related outcomes. LD hub is a centralised database of summary-level GWAS results from 36 GWAS consortia, and provides a web interface to automate multiple LD score regression analyses in a single run. The analyses can be conducted on selected phenotypes of interest or can be carried out on all traits available on the database in hypothesis free tests. We first reformatted GWAS summary statistics for each of the five early growth traits according to the sample input format provided on the developer's website prior to uploading on their server. The diseases/traits of interest for LD score regression analyses were selected from the pre complied list of GWAS available on LD hub where summary statistics are available in the required format for running LD score regression. The LD hub uses pre-calculated LD scores based on European samples. We selected a total of 49 disease/traits of interest from 33 GWAS studies in the following pre-compiled categories: education, anthropometric traits, lipids, glycaemic traits, bone mineral density, neurological / psychiatric diseases and other traits (including adiponectin, CAD, T2D, menarche) and submitted the request for LD score regression for each of the five early growth traits at a time. Following each analysis a genetic correlation matrix between the early growth trait and the selected disease/traits were returned which included the genetic correlation value (rg) its standard error and the corresponding P-value for each trait comparison.
However, LD hub currently does not harbour GWAS summary statistic data for lung function measures or blood pressure traits. To quantify the genetic correlation between early growth phenotypes and these measures we obtained GWAS summary statistics data from the SpiroMeta consortium for the lung function measures of FEV1, FCV, and FEV1/FCV ratio 76 . To generate genetic association statistics for SBP and DBP we carried out GWAS of systolic and diastolic blood pressure (SBP and DBP) using 125,334 subjects from the UK Biobank study 77 (Supplementary Note 3) . For these LD score regression analyses we used the Python scripts provided on the developer's website at https://github.com/bulik/ldsc.
Prior to running the LD score regression analyses each summary statistics file was reformatted using the munge_sumstats.py Python script which filtered the SNPs to HAPMAP 3 SNPs as recommended on the developer's website to minimise any bias from poor imputation quality. SNPs were also excluded if MAF<0.01, ambiguous strand, duplicate rsID and reported sample size is less than 60% of the total available. If the sample size for each SNP was available we used the -N-col to specify the relevant sample size column in the GWAS summary statistics file, and when no sample size column was available we used the maximum sample size reported in the GWAS meta-analysis. After the GWAS summary statistics files were reformatted we then used the ldsc.py Python script to run the LD score regression analyses between each of the six early growth traits, blood pressure and lung function measures. The pre-complied European LD scores calculated from 1000G data available on the developer's website was used for LD score regression. 
